 |
Windows Phones and Unified Communications
Gain a more solid understanding of UC, why it’s essential for your business today, and what makes Windows phones ideal for secure UC environments.
Sponsored by: Microsoft
Date: November 2009 |
|
- Show only
- White Papers
- Webcasts
- Case Studies
- Show all content
- Showing items 1-40 of 670
- « Previous | Next 40 »
|
Millennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis In this article Millennium Pharmaceuticals, Inc and the Brigham and Women's Hospital presented results from seven studies in rheumatoid arthritis (RA) that could pave the... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
 |
IVAX Pharmaceuticals UK Limited Leading American drugs company, IVAX Pharmaceuticals Inc, set up IVAX Pharmaceuticals UK in 1994 in the Royal Docks, east London. In 1994 IVAX Corporation saw... Company: Think London | Think London |
|
Intas Pharmaceuticals Intas Pharmaceuticals established its London office in Harrow, north west London in the summer of 2003. Intas Pharmaceuticals is among the fastest growing pharmaceutical companies... Company: Think London | Think London |
|
FDA Grants Millennium's MLN341 and MLN518 Fast Track Status
This article encapsulates and gives details about Millennium Pharmaceuticals. Millennium Pharmaceuticals is a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform...
Company: Millennium Pharmaceuticals
Date: June 2002 |
Millennium Pharmaceuticals |
|
Variability and Growth in Spending for Outpatient Specialty Pharmaceuticals
Specialty pharmaceuticals are a unique group of drug agents used to treat complex clinical conditions. Many specialty pharmaceuticals are biological in nature and administered through...
Company: Project HOPE
Date: August 2005 |
Project HOPE |
| More Search Results Below | ||
|
Millennium Initiates Combination Oncology Trials of MLN341 With Taxotere
In this article Millennium Pharmaceuticals, Inc. discusses about the initiation of multiple phase I clinical trials of MLN341 (formerly LDP-341, PS-341), in combination with Taxotere...
Company: Millennium Pharmaceuticals
Date: January 2002 |
Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN3897 In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN3897, the first compound to enter clinical trials from... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Pharmaceuticals Industry Action Agenda
This paper, prepared as background to the development of the Pharmaceuticals Industry Action Agenda, presents an analysis of the pharmaceuticals industry and its role in...
Company: Commonwealth of Australia
Date: September 2001 |
Commonwealth of Australia |
|
High-Cost Users of Pharmaceuticals: Who Are They?
For a long time that health care resources and costs are concentrated on a relatively small proportion of the population. These high-level consumers of health...
Company: University of Manitoba
Date: March 2005 |
University of Manitoba |
|
Pharmaceuticals and Industrial Products in Crops: Economic Prospects and Impacts on Agriculture
With modern bio-manufacturing, common crop species can be genetically engineered to synthesize and deliver a broad range of unique bio-molecules needed for medical or industrial...
Company: Iowa State University
Date: November 2004 |
Iowa State University |
|
Best Practices for mySAP Pharmaceuticals
Best Practices for mySAP Pharmaceuticals is an integrated demonstration, evaluation, training, and implementation instrument that provides prepackaged business expertise to enterprises of all sizes. Best...
Company: SAP
Date: December 2001 |
|
|
Business Case: Economic Benefits of EPC in Pharmaceuticals
There is a rapidly growing interest in applying Electronic Product Code (EPC) in pharmaceuticals, not only among drug companies and distributors, but also in the...
Company: Capgemini
Date: November 2004 |
Capgemini |
|
Portals in the Pharmaceuticals Industry
In the pharmaceuticals industry, the overall focus in technology to date has been in implementing transactional ERP. Many of the advantages promised by eCommerce have...
Company: Capgemini
Date: June 2004 |
Capgemini |
|
Major Opportunities For Pharmaceuticals Companies Through Seamless Connections
In the pharmaceuticals industry, the overall focus in technology to date has been in implementing transactional ERP. Many of the advantages promised by eCommerce have...
Company: Cap Gemini Ernst & Young
Date: January 2003 |
Cap Gemini Ernst & Young |
|
Beyond the Blockbuster: Finding the Next Profit Zone in Pharmaceuticals Through Business Design Thinking
The rapid growth of pharmacy companies in the 1990s was driven by a 'blockbuster' model. This model is under pressure: Slowing scientific innovation and rising...
Company: Mercer Management Consulting
Date: April 2003 |
Mercer Management Consulting |
|
Outlook: Potential and Pitfalls in Pharmaceuticals
There are potentially massive profits to be made in the pharmaceuticals' industry, if it can overcome the massive challenges posed by regulation, financing, and globalization,...
Company: President and Fellows of Harvard College
Date: April 2003 |
President and Fellows of Harvard College |
|
Pharmaceuticals/Health Care: Safety and Security in the Spotlight
This article discusses about the safety and security in healthcare and pharmaceutical sector. The U.S. business community?and society in general?have become markedly more security conscious...
Company: Helmers Publishing
Date: June 2004 |
Helmers Publishing |
|
Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses about the initiation of a phase I/II multiple ascending-dose clinical trial of MLN2704 in patients with metastatic androgen-independent...
Company: Millennium Pharmaceuticals
Date: October 2003 |
Millennium Pharmaceuticals |
|
Millennium and Paion to Collaborate on Stroke Program
In this article Millennium Pharmaceuticals, Inc. and PAION GmbH summarize about the agreement to collaborate in the development of MLN519 for patients with stroke and...
Company: Millennium Pharmaceuticals
Date: March 2002 |
Millennium Pharmaceuticals |
|
Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE) 3.5MG Powder for Solution for Injection
In this article Millennium Pharmaceuticals, Inc. informs that it has submitted a complete Marketing Authorization Application (MAA) to the European Agency for the Evaluation of...
Company: Millennium Pharmaceuticals
Date: February 2003 |
Millennium Pharmaceuticals |
|
FDA Accepts for Review NDA Filing and Grants Priority Review for Velcade (Bortezomib) for Injection
In this article Millennium Pharmaceuticals, Inc. reveals that the U.S. Food and Drug Administration (FDA) accepted for review and granted Priority Review designation of the...
Company: Millennium Pharmaceuticals
Date: March 2003 |
Millennium Pharmaceuticals |
|
77 Per Cent of Multiple Myeloma Patients Showed Reduction or Stabilization in Myeloma (M) Protein Levels in Preliminary Phase II Data for Proteasome Inhibitor Bortezomib
In this article Millennium Pharmaceuticals, Inc. discusses their preliminary findings of a phase II clinical trial of its investigational drug bortezomib in patients with multiple...
Company: Millennium Pharmaceuticals
Date: October 2002 |
Millennium Pharmaceuticals |
|
Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer
In this article Millennium Pharmaceuticals, Inc. discusses the initiation of a phase I clinical trial of MLN2704 (formerly known as MLN591DM1) in patients with metastatic...
Company: Millennium Pharmaceuticals
Date: November 2002 |
Millennium Pharmaceuticals |
|
FDA Accepts sNDA Filing With Priority Review for VELCADE (Bbortezomib) for Injection to Treat Second-Line Multiple Myeloma In this article Millennium Pharmaceuticals, Inc. informs that the U.S. Food and Drug Administration (FDA) accepted for review the Company's supplemental New Drug Application (sNDA)... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
XOMA and Millennium Announce Initiation of Phase I Clinical Trial of MLN2222 - a.k.a. CAB-2 - a Novel Complement Inhibitor
In this article, XOMA Ltd. and Millennium Pharmaceuticals, Inc. discusses their initiation of a phase I clinical trial with the complement inhibitor MLN2222 (also known...
Company: Millennium Pharmaceuticals
Date: December 2003 |
Millennium Pharmaceuticals |
|
FDA Approves VELCADE (Bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma This article discusses the Millennium Pharmaceuticals, Inc. approval from the U.S. Food and Drug Administration (FDA) to market VELCADE for the treatment of multiple myeloma... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Millennium Plans to Submit a New Drug Application for Velcade (Bortezomib) for Injection In this article Millennium Pharmaceuticals, Inc. informs that the Company intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration... Company: Millennium Pharmaceuticals | Millennium Pharmaceuticals |
|
Prices and Availability of Pharmaceuticals: Evidence From Nine Countries
This study compares average price levels for pharmaceuticals in eight countries - Canada, Chile, France, Germany, Italy, Japan, Mexico, and the United Kingdom- relative to...
Company: Project HOPE
Date: October 2003 |
Project HOPE |
|
Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries
Parallel imports (PI), also called gray-market imports, are goods produced genuinely under protection of a trademark, patent, or copyright, placed into circulation in one market,...
Company: University of Colorado
Date: April 2001 |
University of Colorado |
|
The Coming Paradigm Shift in Pharmaceuticals
This article explores the coming paradigm shift and the opportunities it presents for the future of pharmaceuticals. This article discusses how Pharmacogenomics holds the promise...
Company: Massachusetts Institute of Technology
Date: September 2002 |
Massachusetts Institute of Technology |
|
Demonstrating the Value of Pharmaceuticals Across the Healthcare Continuum
This document debates and explores medical innovation and the role of pharmaceuticals in the delivery of high-quality healthcare. This article examines and discusses the trends...
Company: Managed Care
Date: February 2004 |
Managed Care |
|
R&D Administration With mySAP Pharmaceuticals
New drug application (NDA) approval is pivotal for pharmaceutical companies. After one wins approval, it's just a matter of marketing and selling the product. But...
Company: SAP
Date: August 2004 |
|
|
The Potential of Plant-Made Pharmaceuticals
With the advent of genetic modification technology, it is now possible to transfer human proteins into crop plants and use the plants as biological factories....
Company: University of Maryland
Date: March 2003 |
University of Maryland |
|
Patents, Innovation and Access to New Pharmaceuticals
This paper considers the role of intellectual property rights in the development of and access to new pharmaceuticals. A number of studies have found patents...
Company: Duke University
Date: July 2002 |
Duke University |
|
Pharmaceuticals and Personal Care Products in the Environment: A White Paper on Options for the Wastewater Treatment Community
This white paper is intended to provide National Association of Clean Water Agencies (NACWA) members with a sense of the state of science on Pharmaceuticals,...
Company: National Association of Clean Water Agencies
Date: November 2005 |
National Association of Clean Water Agencies |
|
Aventis Pharmaceuticals Lowers Injury Rates and Costs With Humantech
Aventis Pharmaceuticals, formerly Rhone-Poulenc Rorer, is a world leader in life sciences dedicated to treating and preventing human disease through the discovery, development, manufacture, and...
Company: Humantech
Date: December 2002 |
Humantech |
|
Amcham 2003 Taiwan White Paper: Pharmaceuticals Taiwan has a healthcare-delivery infrastructure recognized for its world-class technology and the quality of its healthcare workers, but the current funding framework does not permit... Company: Washington State Taiwan Office | Washington State Taiwan Office |
 |
Sales Representative (Pharmaceuticals) Resume
This is a resume template for the post of sales representative (pharmaceuticals). In this template, job descriptions are action-oriented. Courses listed under education are related...
Company: aroj.com
Date: January 2009 |
aroj.com |
|
Vice President Of Sales (Pharmaceuticals) Resume
This is a template for the post of vice-president of sales (pharmaceuticals). In this template, the summary section grabs the reader's attention with powerful skills...
Company: aroj.com
Date: January 2009 |
aroj.com |
|
Annual Report of CollaGenex Pharmaceuticals for the Year 2001
This is the annual report of CollaGenex for the year 2001. The accomplishments of CollaGenex in 2001 were many. In all areas significant achievements helped...
Company: CollaGenex Pharmaceuticals
Date: January 2003 |
CollaGenex Pharmaceuticals |
- Showing items 1-40 of 670
- « Previous | Next 40 »
Submit a Paper
- Get your content listed in our directory! Our members are already finding your competitors' papers here -- shouldn't they find yours, too? It's FREE so click here and submit your white paper, case study, data sheet, research report, or other document today!
